ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 91 Publications

17 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • (B) The sensitivity (LD50) of CLL cells, assessed by annexin V staining after 48 h of treatment with ABT‐737, ABT‐263 or ABT‐199, was plotted against the pBcl‐2/Bcl‐2, Mcl‐1/Bcl‐2 and (pBcl‐2 + Mcl‐1)/Bcl‐2 ratios. Relative protein quantification was carried out with kodak carestream molecular imaging software and normalized to β‐actin. Spearman's correlation (r) and P values are shown. Data shown are representative of five independent experiments.

    Br J Pharmacol, 2016, 173(3):471-83. ABT-737 purchased from Selleck.

    Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

  • Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

    Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

  • Effects of ABT-737 and RES, applied alone and in combination, on the viability of MOLT-4 cells.

    Toxicol In Vitro, 2017, 42:38-46. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • The combined use of ABT-737 and sorafenib changes the apoptotic effect. MC-3 cells were treated with the indicated compounds for 48 h. (A) Nuclear condensation and fragmentation were evaluated in DAPI-stained cells as described in the Materials and Methods (X400). (B) Live (green) and dead (red) cells were qualified using the Live/dead assay kit as described in the Materials and Methods (X200). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)

    Arch Oral Biol, 2017, 73:1-6. ABT-737 purchased from Selleck.

    MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

  • MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MV\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MmG4NlUxKG6PwrC= NF7FSIE4OiCq NYrs[FdqTE2VTx?= Mn\0Z4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> MX:yOlY2PzJ6OB?=
KG1a NU\mc|diS2WubDDWbYFjcWyrdImgRZN{[Xl? NXrPV2sxOC1zMDFOwG0> NIrP[oczPCCq MYPEUXNQ NY\JdHUxUUN3ME23MlY5KM7:TTyg[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NVf0dm5QOjZ3NUK3NVI>
Kasumi-1 NX:3OZBRS2WubDDWbYFjcWyrdImgRZN{[Xl? M1;lNlAuOTBizszN M3LQXVI1KGh? NXfUenBrTE2VTx?= MUHJR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MWGyOlU2OjdzMh?=
KG1a NXnsN|VZSXCxcITvd4l{KEG|c3H5 MYewMVExKM7:TR?= M4PCUlI1KGh? MYXEUXNQ M4TNPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MVWyOlU2OjdzMh?=
Kasumi-1 M4rhSGFxd3C2b4Ppd{BCe3OjeR?= NHfaUYsxNTFyIN88US=> M3Xp[FI1KGh? NXrHWm5sTE2VTx?= MlTlbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MoHDNlY2PTJ5MUK=
MC-3  NGf3TZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LRPVUwOTBxMkCg{txO NVTtWGpTOjRiaB?= MWjEUXNQ NEnyWmhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NXfofYhrOjZ2NEe2NVU>
HN22  M{[zNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkZ|IvPS95LkWvNlIvPSEQvF2= NWi2UFE6OjRiaB?= NHW1SWRFVVOR NHLFUVhqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NIewXoMzPjR2N{[xOS=>
MC-3  NYLJVlJESXCxcITvd4l{KEG|c3H5 MkPKOU8yOC9{MDFOwG0> NWDlfm9GOjRiaB?= MW\EUXNQ NXLyTo9UcW6mdXPld{Bk[XOyYYPlMY1m\GmjdHXkJIFxd3C2b4Ppdy=> M3jwblI3PDR5NkG1
HN22  NFPNZZRCeG:ydH;zbZMhSXO|YYm= NGL3NXkzNjVxNz61M|IzNjVizszN M4DRXVI1KGh? MnT5SG1UVw>? NFHoWlZqdmS3Y3XzJINie3Cjc3WtcYVlcWG2ZXSgZZBweHSxc3nz MVKyOlQ1PzZzNR?=
MOLT-4 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xNE02ODByIH7N NV;BRYlvPzJiaB?= MofFSG1UVw>? MYjJR|UxRTBwMUm4JO69VQ>? MnjMNlY{QTJ|M{K=
RS4;11 MkjSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHXVHAyOC13MECwJI5O M4nUc|czKGh? MlrqSG1UVw>? MYHJR|UxRTBwMECyJO69VQ>? NIKzfGYzPjN7MkOzNi=>
JURKAT MlLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnf3NVAuPTByMDDuUS=> NGjLXos4OiCq MUPEUXNQ NHfo[IpKSzVyPU[2JO69VQ>? MVmyOlM6OjN|Mh?=
CEM R NYmyVY9JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrpUoFvOTBvNUCwNEBvVQ>? NHzYeZY4OiCq NWDtd21TTE2VTx?= MXHJR|UxRTVwNDFOwG0> M4XvVVI3Ozl{M{Oy
CEM S MnnsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jHd|ExNTVyMECgcm0> NUP3UGtSPzJiaB?= MoLpSG1UVw>? MUHJR|UxRTF{LkGg{txO MkL5NlY{QTJ|M{K=
MOLT-4 M13iZ2Fxd3C2b4Ppd{BCe3OjeR?= MlvGNVAuOTByMDDuUS=> NW\6VolWOjRiaB?= NFX6UHBFVVOR MnLvZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= NXT0PYxTOjZ|OUKzN|I>
CEM S MlXiRZBweHSxc3nzJGF{e2G7 NWHRNWxvOTBvMUCwNEBvVQ>? MYSyOEBp MnLKSG1UVw>? MXrjZZV{\XNidHjlJINt\WG4YXflJI9nKEKlbD2yJIFv\CC2aHWg[I94dnKnZ4XsZZRqd25ib3[gRoNtNXiOIHHu[EBO[2xvMR?= MUmyOlM6OjN|Mh?=
JURKAT NGLOS|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX:xNFAuOTByMDDuUS=> MYe0PEBp MlfjSG1UVw>? NV;hNGVnUUN3ME25OVXDuTlwMzDuUS=> MVOyOlE4OjJ4OR?=
LOUCY NUDlNW5YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\X[lExOC1zMECwJI5O MXu0PEBp NVn4[ll{TE2VTx?= M2rVeGlEPTB;M{KuPOKyOTBwOTDuUS=> M2rrZ|I3OTd{Mk[5
WM-115 NUf4RoFES2WubDDWbYFjcWyrdImgRZN{[Xl? MoX4NVAxyqCwTR?= NEDRNGE4OiCq NVe1U5Jk\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= Mnv1NlYyOTZ5N{[=
B16 MV7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWrYOmtiOTBywrDuUS=> NWjwZoRbPzJiaB?= NVjTTXFn\W6qYX7j[ZMh[3W{Y4XtbY4ucW6mdXPl[EBidnSrLYP1dpZqfmGuwrC= M1PKNFI3OTF4N{e2
HL-60  MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\EUVczKGh? NGrn[ItKSzVywrC9JFExNjdibl2= NGnGV|kzPjB2NU[wPS=>
MOLM-13  M2XxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLCO3E4OiCq MmPWTWM2OMLiPTCyO{46KG6P MVSyOlA1PTZyOR?=
OCI-AML3 M{\INGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NkBp MlrJTWM2OMLiPTCxPVUxKG6P NXHUXlZtOjZyNEW2NFk>
BCWM.1 MnvhRZBweHSxc3nzJGF{e2G7 NInPVGwxNTFwNjFOwG0> NHqzT3ozPCCq MWnpcoR2[2W|IHPlcIwh[XCxcITvd4l{ M2TV[|I2QDl|Mkmw
MWCL-1 MYTBdI9xfG:|aYOgRZN{[Xl? MnvHNE0yNjZizszN MknINlQhcA>? MVXpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MWqyOVg6OzJ7MB?=
MM.1s M4L1bWFxd3C2b4Ppd{BCe3OjeR?= M1vWVVAuOS54IN88US=> MWCyOEBp MY\pcoR2[2W|IHPlcIwh[XCxcITvd4l{ Mme2NlU5QTN{OUC=
HCT116 M1fmSWZ2dmO2aX;uJGF{e2G7 NGLM[GY{NzFyIN88US=> NEnIXFgyOsLiaNMg NWLXU2N7TE2VTx?= Ml20bY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHnuZ5Jm[XOnIHnuJGxEO0JvSVmgZ49vfmW{c3nvckBidmRiU2HTWG0yKGSnZ4Lh[IF1cW:w M3rxXFI2PzF3MEK4
HCT116 BAX BAK1 DKO MmXBSpVv[3Srb36gRZN{[Xl? M4i3WFMwOTBizszN M2n0W|EzyqCqwrC= NUjyN4RLTE2VTx?= MXvpcoR2[2W|IHGg[I9{\S2mZYDlcoRmdnRiaX7jdoVie2ViaX6gUGM{Si2LSTDjc453\XK|aX;uJIFv\CCVUWPUUVEh\GWpcnHkZZRqd25? NYfFc2p3OjV5MUWwNlg>
HCT116 NIS0SpVHfW6ldHnvckBCe3OjeR?= NXTEfIlvOTBizszN MWSxNuKhcMLi NITlSVhFVVOR NELQTFBqdmO{ZXHz[ZMhT0[SLVzDN2IheHWwY4Th MkXvNlU4OTVyMki=
HCT116 BAX BAK1 DKO Mm\kSpVv[3Srb36gRZN{[Xl? NYnST5EyOTBizszN NFvk[W8yOsLiaNMg MYrEUXNQ M2TJPYlv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= M{DkUlI2PzF3MEK4
HCT116 MXjBeZRweGijZ4mgRZN{[Xl? MlXONVAh|ryP M2jJS|EzyqCqwrC= MXPEUXNQ MnjsbY5lfWOnczDhJINwdXCuZYTlJIF2fG:yaHHnbYMhemW|cH;ud4U> NG\MXZQzPTdzNUCyPC=>
HCT116 BAX BAK1 DKO MljyRZV1d3CqYXf5JGF{e2G7 NIfuZ3YyOCEQvF2= MXOxNuKhcMLi MYDEUXNQ M2fqOolv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm M1HOPVI2PzF3MEK4
U937 Mnv5RZBweHSxc3nzJGF{e2G7 Mo\HNE4yOjVvMjFOwG0> NYXVbm16OjRiaB?= NFTG[3dmdmijbnPld{BFUEFxWD2xNU1qdmS3Y3XkJIFxd3C2b4Ppdy=> MmfKNlU4OTRyMkS=
U937  M{XY[mFxd3C2b4Ppd{BCe3OjeR?= NH\jeJkxNjVizszN M3rWOlI1KGh? NHLQSpZmdmijbnPld{BkdGWjdnHn[UBw\iCSQWLQJIFv\CClYYPwZZNmNTNiYYOge4VtdCCjczDOc5hiKGyndnXs NV7pS2g6OjV5MUSwNlQ>
HL-60 AAA-Bcl-2 NED2S|VCeG:ydH;zbZMhSXO|YYm= NFTmW5kxNTVizszN NInY[mY1QCCq MmjvTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MV:yOVcyOTR4MB?=
HL-60 EEE-Bcl-2 MV\BdI9xfG:|aYOgRZN{[Xl? M364UFAuPSEQvF2= M1fGWFQ5KGh? NYn5N4VvUUN3ME21JO69de,:jDDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz MlroNlU4OTF2NkC=
U87 Mn\jSpVv[3Srb36gRZN{[Xl? MYC1NEDPxE1? MV6yOEBp NH\GPFZz\WS3Y3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hdGW4ZXzzJI9nKE2PUD2yMEBOVVBvMUSgZY5lKEKlbD2y NEDqPIwzPTZ4N{[2Ny=>
K562 MVjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> Ml;3NU0yOCEQvF2= NHzqcoo1QCCq MkXwSG1UVw>? Mo\jTWM2OD1{Nj63JO69VQ>? MVWyOVU6PjV4MR?=
K562/Mcl -1-IRESBim NVLtdlF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{m0OmlEPTB;OT6zJO69VQ>? MXmyOVU{PTlyMB?=
K562/Bcl- 2-IRESBim MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrjUFZQUUN3ME2wMlM2KM7:TR?= NWrQNHNjOjV3M{W5NFA>
Jurkat MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkOyTWM2OD1yLk[2JO69VQ>? NE\QUm8zPTV|NUmwNC=>
JurkatΔBak M3jRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojuTWM2OD53MDFOwG0> MlvyNlU2OzV7MEC=
HL60/VCR NV;XR|Z7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXS2UpEyUUN3ME6xNFAh|ryP NGnVTHYzPTV|NUmwNC=>
Kasumi-1 NH3VWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rJfWlEPTB;MD6wNUDPxE1? NFO0UlQzPTV|NUmwNC=>
Kasumi-1/ABT NFnPTmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\1XINNUUN3ME2wMlUyKM7:TR?= MXSyOVU{PTlyMB?=
THP-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTFwMkeg{txO NWnjdlNIOjV3M{W5NFA>
U937 NV3DVWN5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LtZWlEPTB;NT6yPUDPxE1? MoXNNlU2OzV7MEC=
C1498 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vvT2lEPTB;Nj6xN{DPxE1? NIPOTlIzPTV|NUmwNC=>
RPMI 8226 NYHoTWFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXsVW1KSzVyPUCuNlUh|ryP M2\nNVI2PTN3OUCw
MM.1S NFLBXmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvmTWM2OD1yLkSwJO69VQ>? MUmyOVU{PTlyMB?=
NCI-H929 NGXMVolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPqTWM2OD1zNT6yNUDPxE1? M3PB[VI2PTN3OUCw
U266 M4DxeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX;JR|UxRTBwNkig{txO NE\iNnEzPTV|NUmwNC=>
MCF-7 NHKwfVVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1\peFUh|ryP MWi0PEBp MnfQSG1UVw>? M{fub4VvcGGwY3XzJJRp\SC|ZX7zbZRqfmm2eTD0c{BweiC{YXTpZZRqd25? M{fMOlI2PDB7MUK0
MCF-7 MXnBdI9xfG:|aYOgRZN{[Xl? M2HDdFUh|ryP NVH1dnY2PC9{ND:0PEBp MmrsSG1UVw>? NI\CeYRqdmO{ZXHz[ZMhfGinIHPs[YF3\WRiUFHSVC=> Mkm2NlU1ODlzMkS=
MCF-7 MljESpVv[3Srb36gRZN{[Xl? MkSyOUDPxE1? M{fjNlI1KGh? M{iy[WROW09? NUSzfm5L\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MWOyOVQxQTF{NB?=
MDA-MB 231  M3HnZmZ2dmO2aX;uJGF{e2G7 NF;ZXJE2KM7:TR?= M4O4UlI1KGh? NWiweodPTE2VTx?= NYi2NZo2\W6qYX7j[ZMhfGinbHX2[Ywhd2ZiTXPsMVEh\XiycnXzd4lwdsLi MkfxNlU1ODlzMkS=
ZR-75-1  NXf2d2d7TnWwY4Tpc44hSXO|YYm= NHHPdY02KM7:TR?= Mnv6NlQhcA>? M{HxbWROW09? M2fs[YVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? NHLGU4ozPTRyOUGyOC=>
A549 M2rj[2NmdGxiVnnhZoltcXS7IFHzd4F6 M3Px[VAuOjBizszN NHLKeZE4OiCq Ml7HSG1UVw>? NIPXVZJl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MoXWNlU{QDh5NkK=
H1299 M{PHSGNmdGxiVnnhZoltcXS7IFHzd4F6 NXv0bFVJOC1{MDFOwG0> MXu3NkBp MX;EUXNQ Monz[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NH;CeoszPTN6OEe2Ni=>
HO-8910 NHr5OVNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NU\Jdm4{OC1{MDFOwG0> MV63NkBp MXPEUXNQ Mn;5[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MXyyOVM5QDd4Mh?=
HT-29 MlHnR4VtdCCYaXHibYxqfHliQYPzZZk> NGjIW2gxNTJyIN88US=> NHfWUlc4OiCq M3foZ2ROW09? NID2Vphl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIh[2:vYnnu[YQhf2m2aDDhd5Bqemmw MmXSNlU{QDh5NkK=
HCT-116 MkD4R4VtdCCYaXHibYxqfHliQYPzZZk> M3L5[VAuOjBizszN NF;xSYk4OiCq MXXEUXNQ MkXG[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? MlewNlU{QDh5NkK=
A549 NWPBfYRbSXCxcITvd4l{KEG|c3H5 MYWyNEDPxE1? NYi0[nNZPDhiaB?= M1rwUWROW09? NEG2d21qdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> MkX6NlU{QDh5NkK=
H1299 M131TmFxd3C2b4Ppd{BCe3OjeR?= M2Pm[|IxKM7:TR?= NFnWd4Y1QCCq NH3MUI1FVVOR NGHW[nVqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIgh[XOyaYLpci=> MUmyOVM5QDd4Mh?=
Sc-1 NFjUR|JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NH3KZlcxNjByMEGtNUDPxE1? MVu5OkBp MlTl[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> MljyNlU{PzN3MEi=
OcI-LY18 NXvuUVRpS2WubDDWbYFjcWyrdImgRZN{[Xl? MkSzNE4xODBzLUGg{txO M3;QRVk3KGh? M1PpV4Rm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NEXtVHgzPTN5M{WwPC=>
RL  M1vRe2NmdGxiVnnhZoltcXS7IFHzd4F6 MV6wMlAxODFvMTFOwG0> M1S2blk3KGh? MkLD[IVkemWjc3XzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NFzsVZczPTN5M{WwPC=>
RKO NYrydXVxS2WubDDWbYFjcWyrdImgRZN{[Xl? NEXhUVUxNTFyIN88US=> M4rsSFI16oDLaNMg NHHOPYtFVVOR NXjPTYxFUUN3ME9ihKkzPeLCidM1US=> M{m3clI2OzB2M{iz
Caco-2 Mo\HR4VtdCCYaXHibYxqfHliQYPzZZk> M33oTFAuOTBizszN Ml3PNlTjiImqwrC= MUDEUXNQ MVXJR|UxRTF7LkhihKnDvU1? M{LDTVI2OzB2M{iz
DLD1 MnfRR4VtdCCYaXHibYxqfHliQYPzZZk> Ml[4NE0yOCEQvF2= NFmwblUzPOLCiXlCpC=> M{jOOGROW09? NVnFZm94UUN3ME2xPE44QOLCidM1US=> NH3DT|EzPTNyNEO4Ny=>
LS411N MUjD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWnYTFBlOC1zMDFOwG0> NH7KO3czPOLCiXlCpC=> NYHvZZhGTE2VTx?= NU\FXnVIUUN3ME2xNU41P+LCidM1US=> MYOyOVMxPDN6Mx?=
SW620 MkTWR4VtdCCYaXHibYxqfHliQYPzZZk> MVOwMVExKM7:TR?= MUmyOQKBkWkEoB?= MXnEUXNQ NEXaTIdKSzVyPUGyMlI16oDLwsXN MmfZNlU{ODR|OEO=
HCT116 M1j3[WNmdGxiVnnhZoltcXS7IFHzd4F6 NULuNYJtOC1zMDFOwG0> NWLE[o9tOjUkgJnoxsA> MXHEUXNQ NXLye3ZyUUN3ME2yNE41QeLCidM1US=> NF64TJczPTNyNEO4Ny=>
HaCaT NYDaVYpFS2WubDDWbYFjcWyrdImgRZN{[Xl? NYH5UYVMOC5zL{GvNVAh|ryP NGnFRnIzPCCq MWXEUXNQ M3XkVYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NI\xSGgzPTJzMEe5OS=>
A5-RT3 NVvSWFlqS2WubDDWbYFjcWyrdImgRZN{[Xl? NH\0[YQxNjFxMT:xNEDPxE1? NHH5[ZIzPCCq NXnkc29bTE2VTx?= NGHzbm1l\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NX7tSYh{OjV{MUC3PVU>
HaCaT MUHGeY5kfGmxbjDBd5NigQ>? MlPPNVDjiIoQvF2= NXLIeIxuOjRxNEigbC=> M1TN[GROW09? NEK0fJlqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= MVOyOVIyODd7NR?=
A5-RT3 MkXwSpVv[3Srb36gRZN{[Xl? M3zvcVEx6oDLzszN MojUNlQwPDhiaB?= MmThSG1UVw>? NEDKNWlqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= MlPWNlUzOTB5OUW=
A5-RT3 NH3tUIlHfW6ldHnvckBCe3OjeR?= NGHoXYs2KM7:TR?= NEO2TYU3KGh? MWrEUXNQ M{GwVIlv\HWlZYOgeIhmKHKnbHXhd4Uhd2ZibXn0c4Npd26mcnnhcEBxem:2ZXnud{BidmRicnXkeYNmeyClbH;uc4dmdmmlIIP1dpZqfmGuIHnuJIEh[2G|cHHz[U1qdmSncHXu[IVvfCCvYX7u[ZI> NVfLXndpOjV{MUC3PVU>
U266 NYLDOpF3TnWwY4Tpc44hSXO|YYm= M4O1SlUxOC95NUCgcm0> MnX3NlQwPDhiaB?= Mo\4SG1UVw>? MYLkc5dvemWpdXzheIV{KEKrbTygdJJqdmOrcHHscJkhfGinIFXMJIl{d2[xcn2= M1LJcFI2OjB6OEi4
RPMI8226 NIHSVlVHfW6ldHnvckBCe3OjeR?= NFz6NG82ODBxN{WwJI5O NX;1fnViOjRxNEigbC=> NFzz[4dFVVOR NXewTIE5\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju MWWyOVIxQDh6OB?=
MM.1S NUGxdWFCTnWwY4Tpc44hSXO|YYm= MYS1NFAwPzVyIH7N NFTsemIzPC92ODDo NIrRd|NFVVOR NITleVNld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> NG\GOFQzPTJyOEi4PC=>
Clone A MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoTnNE4z6oDVNkCg{txO MXS3NkBp MX3EUXNQ MXLJR|UxRTdwNTFOwG0> Ml3ENlUzODh6OEK=
CX-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf6dnF2OC5{4pETOlAh|ryP MoDwO|IhcA>? NX32b4NVTE2VTx?= M1f0U2lEPTB;MT64JO69VQ>? M3n0c|I2OjB6OEiy
LS174T MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTub2dHOC5{4pETOlAh|ryP NXz5eok5PzJiaB?= NVGwT|JKTE2VTx?= MnXvTWM2OD1zOD6zJO69VQ>? M{HkVlI2OjB6OEiy
HT29 MlKyRZBweHSxc3nzJGF{e2G7 MXOxM|UwOTBizszN MoHEOFghcA>? MkfIZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MlX1NlUyQTJzOEi=
SW480 NIPlUZpCeG:ydH;zbZMhSXO|YYm= MnHpNU82NzFyIN88US=> MYe0PEBp M{fxT4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyOVE6OjF6OB?=
Colo205 NV2ySWlLSXCxcITvd4l{KEG|c3H5 NHfmcWYyNzVxMUCg{txO NWn3cGlVPDhiaB?= NGTUR41k[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> NXj4O2RCOjVzOUKxPFg>
Caco2 NF;zTndCeG:ydH;zbZMhSXO|YYm= NGHZSWwyNzVxMUCg{txO NYfpeGpYPDhiaB?= NGnSW5Rk[XW|ZYOgZ4VtdCCmZXH0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=> M4DLRlI2OTl{MUi4
PCI-13 NFjGN25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rxdlczKGh? MX3EUXNQ M{jn[2dKPTB;MUWgxtEhOS56IN88US=> Mne1NlUyOzl|OEe=
PCI-15B NWTBc5NuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r5cFczKGh? NGHXOmZFVVOR MX7HTVUxRTFzINMxJFQvPSEQvF2= MnHLNlUyOzl|OEe=
UM-SCC22B MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrOe4M6PzJiaB?= MkHwSG1UVw>? MXvHTVUxRTF7INMxJFIvQSEQvF2= NFHVSXEzPTF|OUO4Oy=>
UM-SCC47 NWPaVFBZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjIO|IhcA>? NEH0R4FFVVOR NFPZcpRIUTVyPUG5JOKyKDF{LkOg{txO NEexZXczPTF|OUO4Oy=>
93-VU-147T NIXrVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTw[FZ7PzJiaB?= MWPEUXNQ MV3HTVUxRTRwMzFCtUA{NjVizszN NVLVelNLOjVzM{mzPFc>
UD-SCC2 NHS5eJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPF[45vPzJiaB?= M2D1emROW09? NGTvSmpIUTVyPUK4JOKyKDJwOTFOwG0> NW\WV|g3OjVzM{mzPFc>
UPCI:SCC90 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXlZ2Y4OiCq NGi3PZdFVVOR MlLYS2k2OD14Lk[gxtEhOS53IN88US=> MnftNlUyOzl|OEe=
RPMI-8226  M37uTmNmdGxiVnnhZoltcXS7IFHzd4F6 NILpXXIyOjVxMkWwM|UxOCCwTR?= M4HUd|Q5cMLi NFjlNmhFVVOR M3PS[4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NULMboVlOjVyMEiyNFI>
OPM-2  MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MUOxNlUwOjVyL{WwNEBvVQ>? Mn\FOFhpyqB? MWXEUXNQ NFm3SYVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MYSyOVAxQDJyMh?=
RPMI-8226  MVHBdI9xfG:|aYOgRZN{[Xl? NHn0PIQyOjVxMkWwM|UxOCCwTR?= NF\ocWE1QGkEoB?= MWTEUXNQ M4rOe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? M2fZZVI2ODB6MkCy
OPM-2  MnnyRZBweHSxc3nzJGF{e2G7 Ml7DNVI2NzJ3MD:1NFAhdk1? M{e5fFQ5cMLi NXfZRXc4TE2VTx?= M3\xR4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NVHJXpZKOjVyMEiyNFI>
COG-LL-319 MnfxSpVv[3Srb36gRZN{[Xl? NGC0eIwyODBibl2= NEXadlUyNzNxNjDo NYrKUYxDTE2VTx?= NIDRcIlqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen NWfBfIROOjR7NUG0O|I>
RS4;11 NX7LXVh3TnWwY4Tpc44hSXO|YYm= MYKxNFAhdk1? NXvO[YZNOS9|L{[gbC=> MmDtSG1UVw>? NInm[2ZqdmS3Y3XzJINie3Cjc3Wt[IVx\W6mZX70JG1kdC1zIHPs[YF3[Wen MkHsNlQ6PTF2N{K=

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay:

[1]

+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research:

[4]

+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% Propylene glycol, 5% Tween 80, 65% D5W
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID